Vet-OncoNet: Malignancy Analysis of Neoplasms in Dogs and Cats

The Beneficial Use of Artemisia annua, Artemisinin, and Other Compounds in Animal Health

Plants and plant-derived natural products have been used in traditional medicine for centuries. The lack of effective therapies in the modern world to address several diseases, the increasing development of drug resistance, and the growing interest in herbal medicine have led to the study and resurgence of natural ancient remedies. A. annua, commonly known as sweet wormwood or sweet annie, is a medicinal plant widely known for its antimalarial properties. In the past decade, increasing evidence has demonstrated the plant's broad therapeutic potential, including antitumoral, antimicrobial, antiparasitic, metabolic, and immunomodulatory effects, among others. While most research has focused on human health, there is growing interest in exploring the veterinary applications of A. annua and its bioactive compounds, particularly artemisinin. This review aims to summarize the current knowledge on the beneficial effects of A. annua, artemisinin, and other compounds in animal health. It also highlights the need for standardizing A. annua metabolites to ensure the reliability and efficacy of treatments and explores how artemisinin works in synergy with other molecules present in A. annua.

A novel cross-validated machine learning based Alertix-Cancer Risk Index for early detection of canine malignancies

Introduction

The demand for non-invasive tumor biomarkers in veterinary field has recently grown significantly. Thymidine kinase 1 (TK1) is one of the non-invasive proliferation biomarkers that has been used for diagnosis and treatment monitoring of different canine malignancies. However, recent studies showed that the combination of TK1 with inflammatory biomarkers such as canine C-reactive protein (cCRP) can enhance the sensitivity for early tumor detection. Herein, we developed a machine learning (ML) model, i.e., Alertix-Cancer Risk Index (Alertix-CRI) which incorporates canine TK1 protein, CRP levels in conjunction with an age factor.

Methods

A total of 287 serum samples were included in this study, consisting of 67 healthy dogs and dogs with different tumors (i.e., T-cell lymphoma n = 24, B-cell lymphoma n = 29, histiocytic sarcoma n = 47, hemangiosarcoma n = 26, osteosarcoma n = 26, mastocytoma n = 40, and mammary tumors n = 28). Serum TK1 protein levels were measured using TK1-ELISA and cCRP levels by a quantitative ELISA. The whole data set was divided as training (70%) and validation (30%). The Alertix-Cancer Risk Index (Alertix-CRI) is a generalized boosted regression model (GBM) with high accuracy in the training set and further validation was carried out with the same model.

Results

Both the TK1-ELISA and cCRP levels were significantly higher in the tumor group compared to healthy controls (p < 0.0001). For overall tumors, the ROC curve analysis showed that TK1-ELISA has similar sensitivity as cCRP (54% vs. 51%) at a specificity of 95%. However, the Alertix-CRI for all malignancies showed an area under the curve (AUC) of 0.98, demonstrating very high discriminatory capacity, with a sensitivity of 90% and a specificity of 97%.

Conclusion

These results demonstrate that the novel Alertix-CRI could be used as a decision-support tool helping clinicians to early differentiate dogs with malignant diseases from healthy. Additionally, these findings would facilitate the advancement of more precise and dependable diagnostic tools for early cancer detection and therapy monitoring within the realm of veterinary medicine.

Exploring canine mast cell tumors: An investigation into demographic characteristics, and grading system analysis from a pathology lab data (2019-2021)

Mast cell tumors (MCT) are among the most common neoplasia in dogs, representing up to 21 % of skin tumors. However, etiology and risk factors for its development remain unclear. This study aimed to reduce this knowledge gap by comprehensively analyzing 905 MCT cases diagnosed in Portugal between 2019 and 2021, using descriptive and inferential analyses. Most tumors affected the skin, with 69.9 % and 21.2 % classified as cutaneous and subcutaneous tumors, respectively. Only subcutaneous MCT exhibited female predisposition. Breed-specific analyses revealed male predominance in French Bulldogs and female predominance in Shar-Peis. Tumors in the extremities were the most prevalent (43.2 %, n = 183). Age-related characteristics varied by breed, with Pugs, Boxers, French Bulldogs, and Shar-Peis being diagnosed at younger ages. Logistic regression showed that age increased the likelihood of developing higher-grade cutaneous tumors (p < 0.01, OR=1.17, 95 % CI 1.02-1.21) and subcutaneous tumors with an infiltrative pattern (p = 0.02, OR=1.17, 95 % CI: 1.04 -1.33). The estimated annual incidence risk for MCT in dogs from Lisbon and Setúbal districts is 3.1 cases per 10,000 dogs, and 3.0 for males and 3.2 for females. Compared to mixed-breed dogs, Boxers, Shar-Peis, and Golden Retrievers had significantly higher relative risks (7.1, 6.3, and 5.9, respectively, p < 0.01). Sex-specific relative risks showed Boxers with the highest values among males (9.9, p < 0.01) and Shar-Peis among females (8.0, p < 0.01). This study provides insights into canine MCT, emphasizing the importance of age, sex, and breed, as well as the need for tailored veterinary care that considers these demographic characteristics to enhance prevention, early detection, and management.

Advancing Veterinary Oncology: Next-Generation Diagnostics for Early Cancer Detection and Clinical Implementation

Cancer is a leading cause of death among companion animals, with many cases diagnosed at advanced stages when clinical signs have appeared, and prognosis is poor. Emerging diagnostic technologies, including Artificial Intelligence (AI)-enhanced imaging, liquid biopsies, molecular diagnostics, and nematode-based screening, can improve early detection capabilities in veterinary medicine. These tools offer non-invasive or minimally invasive methods to facilitate earlier detection and treatment planning, addressing the limitations of traditional diagnostics, such as radiography and tissue biopsies. Recent advancements in comparative oncology, which leverage the biological similarities between human and companion animal cancers, underscore their translational value in improving outcomes across species. Technological advances in genomics, bioinformatics, and machine learning are driving a shift toward precision medicine, enabling earlier detection, personalized treatments, and monitoring of disease progression. Liquid biopsy testing detects circulating tumor DNA and tumor cells, providing actionable insights into tumor genetics without invasive procedures. Imaging systems enhance diagnostic precision, offering consistent and accurate tumor identification across veterinary practices, while portable innovations like Caenorhabditis elegans-based screening provide accessible options for underserved regions. As these technologies migrate from human medicine to veterinary applications, they are poised to redefine cancer care for companion animals. This review highlights key advancements in diagnostic technologies and their application in veterinary oncology, with a focus on enhancing early detection, accessibility, and precision in cancer care. By fostering the adoption of these innovations, veterinary oncology can achieve a new standard of care, improving outcomes for both animals and humans through the lens of comparative oncology.

Outcome of treatment with a 10-week COP protocol in cats with intermediate or large cell lymphoma: 27 cases (2014-2023)

OBJECTIVES

The aim of this retrospective clinical study was to evaluate and report response to treatment with a 10-week maintenance-free COP (COP-10) protocol in a cohort of 27 cats with intermediate or large cell lymphoma. Additionally, to identify any potential prognostic factors for predicting the treatment response.

MATERIALS AND METHODS

The medical records of cats diagnosed with intermediate or large cell lymphoma in a single institution in the period 2014 to 2023 and treated with COP-10 as first-line treatment were reviewed.

RESULTS

Twenty-seven cats were included in the study. The median age was 10 years, 67% of the cats were in stages I to II and the most common anatomical location was alimentary (37%). The overall response rate was 65%, with 38% of cats achieving complete remission and 27% partial remission. For cats achieving complete remission, the median progression-free interval and the median lymphoma-specific survival time were both 1,139 days. For cats in partial remission, the median progression-free interval and the median lymphoma-specific survival time were 53 and 210 days, respectively. Clinical stage was significantly related to treatment response and survival time.

CLINICAL SIGNIFICANCE

Treatment with the short protocol COP-10 resulted in remission rates and durable first remissions for cats achieving complete remission comparable to responses seen with longer-duration chemotherapy protocols. The results from this study may impact economic and logistic decisions for owners, as well as the quality of life for patients in the future.

The beauty of the beast: Suggestions to curb the excesses of dog breeding and restore animal welfare - Invited review

Dog. Specifically created to save its master's life. - (The dog is the ideal) Friend of man, (because it is his devoted slave) (source: Gustave Flaubert, Dictionnaire des Idées Reçues). But is man the best friend of the dog? This question is legitimate when we consider living situations to which modern domestic dogs are exposed. They often do not satisfy basic animal needs. In this narrative review, the author revisits the history of the dog's presence alongside humans, in the light of current knowledge. The modern dog (breed standards and their interests in canine research) and its breeding strategy, including extreme breeding, will then be given particular attention. Dysfunctional human psychological processes will be explored to make it possible to grasp why the breeding of the modern dog is undergoing such a transformation. Finally, based on these factual and conceptual insights, suggestions to improve canine welfare will be proposed. To be effective, all these must be assessed against real-world conditions.

Pathology-Based Animal Cancer Registry of Abruzzo and Molise Regions (Central Italy): A Ten-Year Retrospective Study (2014-2023)

Pets have a crucial role in cancer research. Specifically, dogs and cats share the same environment as their owners and thus may serve as sentinels of naturally occurring tumors that are linked to the exposure to environmental hazards. Quantitative comparison of tumor types may reveal unusual cancer frequencies, providing directions for research and generation of hypotheses of cancer causation in a specific area and identification of risk factors. The aim of this study was to describe the data collected by the pathology-based animal cancer registry, managed by Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise (IZSAM), during 10 years of activity (2014-2023) and to assess its potential epidemiological relevance. Frequencies of tumor topography and morphology in dogs and cats were described, analyzed and compared. Proportional morbidity ratios (PMRs) were calculated, taking into consideration some potential risk factors such as species, breed, sex, diet and living environment. The database comprises 5311 tumors (n = 4719 in dogs and n = 592 in cats), with a higher prevalence in females (67.3% in dogs and 61.2% in cats). The mean age at the first diagnosis of tumors was similar between sexes and slightly lower in dogs compared to cats. PMRs highlighted certain risk and "protective" factors for the development of tumors in specific topography. The risk of developing tumors of the blood and hematopoietic system (PMR = 0.44; 95% CI: 0.21-0.94), skin and subcutaneous tissues (PMR = 0.70; 95% CI: 0.61-0.80), oral cavity and pharynx (PMR = 0.60; 95% CI: 0.24-0.89), urinary organs (PMR = 0.33; 95% CI: 0.11-0.99) and bones, joints and cartilage (PMR = 0.72; 95% CI: 0.22-0.98) was lower in non-neutered male dogs than in neutered male dogs. Non-spayed female dogs had a greater risk of developing tumors of the mammary gland (PMR = 1.75; 95% CI: 1.57-1.96), female sexual organs (PMR = 2.12; 95% CI: 1.01-4.36) and respiratory system (PMR = 2.25; 95% CI: 1.55-6.74) but less risk for cutaneous and subcutaneous tissue tumors (PMR = 0.44; 95% CI: 0.38-0.51) and blood/hematopoietic system tumors (PMR = 0.47; 95% CI: 0.26-0.85) compared to spayed female dogs. Compared with mixed breed, purebred dogs had a significantly greater risk of developing mammary gland tumors (PMR = 1.36; 95% CI: 1.20-1.54) and lower risk for respiratory (PMR = 0.15; 95% CI: 0.07-0.32), gastrointestinal (PMR = 0.63; 95% CI: 0.34-0.94) and oral (PMR = 0.59; 95% CI: 0.36-0.96) neoplasia. Non-neutered male cats had a lower risk of developing skin and subcutaneous tumors (PMR = 0.68; 95% CI: 0.50-0.92) compared with neutered cats. The risk of developing skin and subcutaneous tissues tumors was higher for dogs and cats that lived mostly outdoor (PMR dogs = 1.21; 95% CI: 1.10-1.33; PMR cats = 1.18; 95% CI: 1.08-1.47), while dogs that live mainly indoor had a greater risk to develop mammary gland tumors (PMR = 0.78; 95% CI: 0.68-0.89). Results described herein highlight the fundamental role of animal cancer registration initiatives. These efforts would contribute to the possibility of conducting multicentric collaborative studies to deepen the knowledge of the epidemiology of tumors in dogs and cats from a comparative perspective, thus fulfilling the One Health approach.

Regional Variations in and Key Predictors of Feline Tumor Malignancy: A Decade-Long Retrospective Study in Korea

Feline cancer is increasingly recognized as a major cause of mortality, yet data on tumor prevalence and behavior in cats, particularly in non-Western regions, remain limited. This study analyzed a decade of feline tumor data in Korea from 2012 to 2022, focusing on age, breed, and anatomical location as predictors of malignancy. Data were collected from 683 cats, with regression analysis applied to determine significant associations. Older cats exhibited a markedly higher risk of malignancy, particularly in mast cell and mammary tumors. Tumors in the mammary gland and alimentary tract had malignancy rates exceeding 90%, underscoring the need for early detection in these regions. Interestingly, squamous cell carcinoma was rare in the skin, in stark contrast to Western studies, likely reflecting differences in environmental exposure. While breed was not a statistically significant predictor, certain breeds, including Persians and Russian Blues, showed a higher frequency of malignancy. These findings highlight the importance of regional tumor research in cats and the need for larger, multicenter datasets that incorporate environmental, genetic, and lifestyle factors. Understanding these influences will help refine veterinary care and improve cancer treatment outcomes in feline populations.

Age at Tumor Diagnosis in 14,636 Canine Cases from the Pathology-Based UNIPI Animal Cancer Registry, Italy: One Size Doesn't Fit All

Cancer is the most common cause of death in adult dogs. All dogs would benefit from early diagnosis, but there are no specific guidelines regarding the schedule of cancer screening in companion animals. The aim of this study was to retrospectively evaluate the age at diagnosis in Italian oncological canine patients. A total of 14,636 canine histologically confirmed neoplastic cases were coded according to the Vet-ICD-O-canine-1 and stratified by malignancy, sex, neutering status, breed, cephalic index, body size, and tumor type. Differences in age distribution were analyzed and the influence of these variables on the time of first malignancy diagnosis was assessed using an event history analysis model. The median age at diagnosis for benign and malignant tumors was 9 and 10 years, respectively. Intact and purebred dogs were diagnosed earlier, but the median age differed significantly by breed. The earliest age at diagnosis was recorded for lymphomas and mast cell tumors. The model showed an accelerating effect of large size, brachy- and dolichocephaly, and sexual integrity in female dogs on the time of malignancy diagnosis. Our results confirm that a "one-size-fits-all" approach to cancer screening is not accurate in dogs and provide relevant data that may lead to the establishment of breed-based screening schedules.

Spontaneous tumours in dogs: A clinical and pathomorphological study in Kyrgyzstan

The aim of this study is to investigate the correlation between the incidence of spontaneous tumours of various origins and the localisation in dogs with sex, breed, and age factors. A total of 360 tumours with various localisation were studied pathomorphologically. Histopathologic data sets from 360 dog tissue samples were processed and statistically examined. A chi-square test of independence was conducted to examine the relationships among the various levels of the specified variables. Logistic regression models were employed for dichotomous outcomes to ascertain the influence of certain explanatory variables on the tumour types. Characteristic pathomorphological changes observed during examination of dogs with oncologic diseases were determined. The most common neoplasms were mammary tumours, accounting for 43% of the cases. The mammary gland tumours were most common in mongrel dogs (25%), with German Shepherds (17.3%), Poodles, Dachshunds, Central Asian Shepherds (6.7% each), and Rottweilers (5.7%) following. The highest frequency of these tumours appeared at 8 years of age, predominantly originating from the ductal epithelium, which represented 46.4% of all the malignant cases.

Incidence rates of the most common canine tumors based on data from the Swiss Canine Cancer Registry (2008 to 2020)

Monitoring neoplasms in standardized registries facilitates epidemiologic studies of risk factors for tumor development and predisposition. In an observational study, we determined incidence rates (IR) and malignant tumor incidence rate ratios (IRR) by age, sex, and breed in Swiss dogs using demographic data from the official Swiss dog registration database Amicus. The dataset analyzed included 54'986 tumors diagnosed by histology and cytology in four Swiss veterinary pathology laboratories between 2008 and 2020. Diagnoses were coded according to the Vet-ICD-O-canine-1 system. Most tumors occurred in the skin (n = 19'045; 34.64%), soft tissues (n = 11'092; 20.17%), and mammary glands (n = 7'974; 14.50%). The IRs for all and for malignant tumors were 775/100'000 dog-years at risk (95%CI 764-777) and 338/100'000 dog-years at risk (95%CI 333-342), respectively. Females (850; 95%CI 834-853) had a higher overall tumor IR than males (679; 95%CI 666-684). The highest tumor IR was found at 11 years of age (1'857; 95%CI 1'780-1'867). Potential novel breed-specific predispositions were uncovered, with high IRs for several benign and malignant tumors in Polski Owczarek Nizinnys (overall IR: 3'303; 95%CI 2'502-3'864) and high IRs for malignant tumors in Russian Black Terriers (melanomas: 345; 95%CI 138-708), Field Spaniels (adenocarcinomas: 376; CI95% 138-817), Dogo Argentinos (mast cell tumors: 844; CI95% 591-1'169), King Charles Spaniels and Manchester Terriers (lymphomas: 319; CI95% 137-627 and 302; CI95% 98-704, respectively), Landseers (osteosarcomas: 74; CI95% 15-216), Bouvier des Flandres (hemangiosarcomas: 127; CI95% 26-371), and Bearded Collies and Cane Corso Italianos (gliomas: 91; CI95% 45-162 and 34; CI95% 7-99, respectively). Nordic hunting dogs had the highest (8.08; CI95% 3.55-16.7) and Chihuahueno the lowest cancer IRRs (0.42; 95%CI 0.31-0.57) compared to mixed breeds. In conclusion, the calculated IRs and IRRs revealed previously unknown predisposing factors, including novel breed-specific susceptibilities. The results may have implications for cancer screening, diagnostic work-up, breeding management and oncologic and translational research.

Anaesthesia in Veterinary Oncology: The Effects of Surgery, Volatile and Intravenous Anaesthetics on the Immune System and Tumour Spread

Throughout the course of oncological disease, the majority of patients require surgical, anaesthetic and analgesic intervention. However, during the perioperative period, anaesthetic agents and techniques, surgical tissue trauma, adjuvant drugs for local pain and inflammation and other non-pharmacological factors, such as blood transfusions, hydration, temperature and nutrition, may influence the prognosis of the disease. These factors significantly impact the oncologic patient's immune response, which is the primary barrier to tumour progress, promoting a window of vulnerability for its dissemination and recurrence. More research is required to ascertain which anaesthetics and techniques have immunoprotective and anti-tumour effects, which will contribute to developing novel anaesthetic strategies in veterinary medicine.